These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 29770723)

  • 1. The impact of azole antifungal drugs on imatinib metabolism in human liver microsomes.
    Luo X; Li T; Yu Z; Xue X; Zhao H; Li N; Ma L; Yang C; Huang L; Feng W
    Xenobiotica; 2019 Jul; 49(7):753-761. PubMed ID: 29770723
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of voriconazole and other azole antifungal agents on CYP3A activity and metabolism of tacrolimus in human liver microsomes.
    Zhang S; Pillai VC; Mada SR; Strom S; Venkataramanan R
    Xenobiotica; 2012 May; 42(5):409-16. PubMed ID: 22106961
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Azole antifungal inhibition of buprenorphine, methadone and oxycodone in vitro metabolism.
    Moody DE; Liu F; Fang WB
    J Anal Toxicol; 2015 Jun; 39(5):374-86. PubMed ID: 25868557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azoles, allylamines and drug metabolism.
    Back DJ; Tjia JF; Abel SM
    Br J Dermatol; 1992 Feb; 126 Suppl 39():14-8. PubMed ID: 1311943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Midazolam alpha-hydroxylation by human liver microsomes in vitro: inhibition by calcium channel blockers, itraconazole and ketoconazole.
    Wang JS; Wen X; Backman JT; Taavitsainen P; Neuvonen PJ; Kivistö KT
    Pharmacol Toxicol; 1999 Oct; 85(4):157-61. PubMed ID: 10563513
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes.
    Niwa T; Shiraga T; Takagi A
    Biol Pharm Bull; 2005 Sep; 28(9):1805-8. PubMed ID: 16141567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative effects of the antimycotic drugs ketoconazole, fluconazole, itraconazole and terbinafine on the metabolism of cyclosporin by human liver microsomes.
    Back DJ; Tjia JF
    Br J Clin Pharmacol; 1991 Nov; 32(5):624-6. PubMed ID: 1659439
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
    Gupta A; Unadkat JD; Mao Q
    J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Differential Impacts of Azole Antifungal Drugs on the Pharmacokinetic Profiles of Dasatinib in Rats by LC-MS-MS.
    Luo X; Xue X; Li T; Zhang Y; Huang L; Cheng G
    Curr Drug Metab; 2020; 21(13):1022-1030. PubMed ID: 33092505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Substrate Specificity of Human Cytochrome P450 (CYP) 2C Subfamily and Effect of Azole Antifungal Agents on CYP2C8.
    Niwa T; Imagawa Y
    J Pharm Pharm Sci; 2016; 19(4):423-429. PubMed ID: 28057172
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Drug interactions between nine antifungal agents and drugs metabolized by human cytochromes P450.
    Niwa T; Imagawa Y; Yamazaki H
    Curr Drug Metab; 2014; 15(7):651-79. PubMed ID: 25429674
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Drug-drug interaction of antifungal drugs].
    Niwa T; Shiraga T; Takagi A
    Yakugaku Zasshi; 2005 Oct; 125(10):795-805. PubMed ID: 16205037
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inhibition of cytochrome P-450 3A (CYP3A) in human intestinal and liver microsomes: comparison of Ki values and impact of CYP3A5 expression.
    Gibbs MA; Thummel KE; Shen DD; Kunze KL
    Drug Metab Dispos; 1999 Feb; 27(2):180-7. PubMed ID: 9929500
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Azole antifungal agents.
    Bodey GP
    Clin Infect Dis; 1992 Mar; 14 Suppl 1():S161-9. PubMed ID: 1314105
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical relevance of the pharmacokinetic interactions of azole antifungal drugs with other coadministered agents.
    Brüggemann RJ; Alffenaar JW; Blijlevens NM; Billaud EM; Kosterink JG; Verweij PE; Burger DM
    Clin Infect Dis; 2009 May; 48(10):1441-58. PubMed ID: 19361301
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of two azole antifungal drugs, ketoconazole, and fluconazole, as modifiers of rat hepatic monooxygenase activity.
    Houston JB; Humphrey MJ; Matthew DE; Tarbit MH
    Biochem Pharmacol; 1988 Feb; 37(3):401-8. PubMed ID: 2827686
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Molecular mechanisms of posaconazole- and itraconazole-induced pseudohyperaldosteronism and assessment of other systemically used azole antifungals.
    Beck KR; Telisman L; van Koppen CJ; Thompson GR; Odermatt A
    J Steroid Biochem Mol Biol; 2020 May; 199():105605. PubMed ID: 31982514
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oral Azole Antifungal Medications and Risk of Acute Liver Injury, Overall and by Chronic Liver Disease Status.
    Lo Re V; Carbonari DM; Lewis JD; Forde KA; Goldberg DS; Reddy KR; Haynes K; Roy JA; Sha D; Marks AR; Schneider JL; Strom BL; Corley DA
    Am J Med; 2016 Mar; 129(3):283-91.e5. PubMed ID: 26597673
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.
    Lin G; Wang C; Qiu X; Wang Z; Han A; Xu T; Kan X; Hu G
    Drug Dev Ind Pharm; 2014 Dec; 40(12):1616-22. PubMed ID: 24053419
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of oral posaconazole on the pharmacokinetic properties of oral and intravenous midazolam: a phase I, randomized, open-label, crossover study in healthy volunteers.
    Krishna G; Moton A; Ma L; Savant I; Martinho M; Seiberling M; McLeod J
    Clin Ther; 2009 Feb; 31(2):286-98. PubMed ID: 19302901
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.